At a glance
ClinicalIndex Comparison RecordN/ACompleted· 181 enrolled
Drug / intervention
AcrySof IQ PanOptix Presbyopia Correcting IOL +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Market Clinical Study of the AcrySof® IQ PanOptix® Presbyopia Correcting Intraocular Lens in a Chinese Population
In Brief
A clinical study evaluating AcrySof IQ PanOptix Presbyopia Correcting IOL and Cataract surgery for Aphakia and Presbyopia. Completed, enrolled 181 participants across 9 sites.
Detailed Summary
The primary objective of this clinical study is to assess the clinical performance of the PanOptix IOL in a Chinese population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAphakia, Presbyopia
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartApr 2021
Primary CompletionAug 2022
Study CompletionMar 2023
TodayJul 2026
First PostedFeb 16, 2021
Enrollment StartApr 19, 2021
Primary CompletionAug 31, 2022
Study CompletionMar 15, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago
Interventions
AcrySof IQ PanOptix Presbyopia Correcting IOLdevice
UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
Cataract surgeryprocedure
Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL